Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. (ATRC) delivers pioneering medical technologies for cardiac arrhythmia treatment and minimally invasive surgical solutions. This dedicated news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and regulatory milestones.
Access timely information on FDA-cleared devices, atrial fibrillation treatment innovations, and strategic partnerships. Our curated collection includes earnings reports, product launch announcements, and peer-reviewed study results directly impacting cardiac care practices.
Key updates cover ablation system enhancements, left atrial appendage management solutions, and operational expansions. Bookmark this page for structured access to AtriCure's latest advancements in electrophysiology and cardiothoracic surgical technologies.
AtriCure (NASDAQ:ATRC), a leader in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the 2025 Wells Fargo Healthcare Conference.
The company's management will engage in a fireside chat on September 3, 2025, at 3:45 p.m. EST. Investors and interested parties can access the live audio webcast through AtriCure's investor relations website at ir.atricure.com.
AtriCure (NASDAQ:ATRC), a leader in surgical treatments for atrial fibrillation, reported strong Q2 2025 financial results and raised its outlook. The company achieved revenue of $136.1 million, up 17.1% year-over-year, with U.S. revenue at $110.6 million (+15.7%) and international revenue at $25.6 million (+23.3%).
Key highlights include a net loss improvement to $6.2 million from $8.0 million year-over-year, and Adjusted EBITDA of $15.4 million, increasing by $7.6 million. The company generated $17.9 million in cash during the quarter and completed enrollment of 6,500 patients in the LeAAPS trial.
AtriCure raised its 2025 guidance, now projecting full-year revenue of $527-533 million and Adjusted EBITDA of $49-52 million. The company expects modest cash flow generation for 2025.
AtriCure (NASDAQ:ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference.
The company's management team will deliver their presentation on Tuesday, August 12, 2025, at 2:30 p.m. EST. Investors and interested parties can access the live audio webcast through the Investors section of AtriCure's website.
AtriCure (NASDAQ: ATRC) has completed enrollment in its landmark LeAAPS clinical trial, the largest cardiac surgery device trial ever conducted with 6,500 patients across 137 centers globally. The trial evaluates the AtriClip® LAA Exclusion System for stroke prevention in cardiac surgery patients without pre-existing atrial fibrillation.
The study targets a significant market opportunity, as over one million cardiac surgery procedures occur annually, with more than 70% of patients having no prior Afib history. The trial, initiated in January 2023, will continue with five years of follow-up to assess long-term outcomes. AtriCure aims to use the trial data to support an expanded indication for stroke prevention in high-risk patients.
AtriCure (NASDAQ: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has scheduled its second quarter 2025 financial results announcement for Tuesday, July 29, 2025.
The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss the quarterly results. Interested participants should register online in advance, preferably 15 minutes before the call starts. Both live and replay versions of the webcast will be accessible through AtriCure's investor relations website.
AtriCure (NASDAQ: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will conduct a fireside chat on June 9, 2025, at 4:00 p.m. EST. Investors and interested parties can access the live audio webcast through AtriCure's investor relations website at https://ir.atricure.com.
AtriCure reported strong Q1 2025 financial results with worldwide revenue reaching $123.6 million, marking a 13.6% year-over-year increase. The company showed significant improvement in its net loss position, reducing it to $6.7 million from $13.3 million in the previous year.
Key highlights include:
- U.S. revenue grew 12.1% to $101.1 million
- International revenue increased 20.8% to $22.5 million
- Gross margin improved to 74.9%
- Adjusted EBITDA reached $8.8 million, up by $6.0 million
Growth was driven by strong sales across product lines, including the EnCompass clamp, cryoSPHERE MAX probes, and AtriClip Flex·Mini device. Management updated 2025 guidance, projecting full-year revenue between $517-527 million and adjusted EBITDA of $44-46 million.
AtriCure (Nasdaq: ATRC) has announced the first use of its newly FDA-cleared AtriClip PRO-Mini® LAA Exclusion System, designed for minimally invasive concomitant procedures. The device represents a significant advancement in left atrial appendage (LAA) management technology.
The innovative device features a 60% smaller profile compared to the next lowest profile AtriClip device, providing surgeons with enhanced visualization and precise LAA exclusion capabilities. Key benefits include uniform pressure application for reliable closure, omnidirectional head articulation, and streamlined applier removal.
Dr. Ahmed Romeya from Midwest Heart and Vascular Specialists highlighted the device's smaller profile and parallel closure capabilities, noting increased surgeon confidence during procedures. This latest addition builds upon AtriCure's 20+ year legacy in surgical appendage management and their position as the provider of the most widely implanted surgical LAA device globally.
AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has scheduled the release of its first quarter 2025 financial results for Tuesday, April 29, 2025.
The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss the quarterly results. Interested participants are advised to register online more than 15 minutes before the call begins. Both live and replay versions of the webcast will be accessible through the company's investor relations website.
AtriCure (Nasdaq: ATRC), a pioneer in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its upcoming Analyst & Investor Day scheduled for March 26, 2025.
The event will take place at the company's headquarters in Mason, Ohio, running from 1:00 PM to 4:00 PM ET. During the presentation, AtriCure will showcase its product portfolio and innovative pipeline for market expansion, featuring insights from key opinion leaders and sharing long-term financial objectives focused on growth and increased profitability.
Interested parties can access both live and archived webcasts of the presentation and Q&A sessions through the Investors section of AtriCure's website at https://ir.atricure.com.
FAQ
What is the current stock price of Atricure (ATRC)?
What is the market cap of Atricure (ATRC)?
